BioMarin to Present at the Oppenheimer Healthcare Conference

* Reuters is not responsible for the content in this press release.

Tue Oct 27, 2009 4:00pm EDT 

NOVATO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.
(Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer of
BioMarin, will present a company update at the Oppenheimer Healthcare
Conference in New York City on Tuesday, November 3, 2009 at 1:35 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via
the investor section of the BioMarin website, www.BMRN.com.  A replay of the
call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
three approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis
I (MPS I), a product which BioMarin developed through a 50/50 joint venture
with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets,
for phenylketonuria (PKU), developed in partnership with Merck Serono, a
division of Merck KGaA of Darmstadt, Germany. Other product candidates include
PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in Phase
II clinical development for the treatment of PKU and GALNS
(N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical
development for the treatment of MPS IVA. For additional information, please
visit www.BMRN.com. Information on BioMarin's website is not incorporated by
reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin
Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                             Media
    Eugenia Shen                          Susan Berg
    BioMarin Pharmaceutical Inc.          BioMarin Pharmaceutical Inc.
    (415) 506-6570                        (415) 506-6594




SOURCE  BioMarin Pharmaceutical Inc.

Investors, Eugenia Shen, +1-415-506-6570, or Media, Susan Berg,
+1-415-506-6594, both of BioMarin Pharmaceutical Inc.
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.